About JB Chemicals & Pharmaceuticals Ltd.



JB Chemicals & Pharmaceuticals Limited (JBCPL), is an Indian pharmaceutical company headquartered in Mumbai, Maharashtra, India. Established in 1976 by Mr. JB Mody and his brothers, Mr. DB Mody and Mr. SB Mody, the company manufactures and markets pharmaceutical formulations, herbal remedies and APIs – both domestically and to 30-plus countries worldwide, including the United States, Europe, Australia, South Africa, other developing countries, Russia and CIS.


JBCPL’s three main businesses include:

  1. Domestic Formulations (2015-16 sales: ?423.32 crores), including cardiac, dermatological, gastro, anti-hypertensive and contrast media products. The company was ranked 35 in the domestic industry (IMS MAT, March 2016), with the following 3 brands featuring among top 300 in terms of value and units:
    • Rantac (antipeptic ulcerant)
    • Cilacar (calcium channel blocker)
    • Metrogyl (amoebicides

Its recently launched category creator brand, Rantac Syrup, ranks #1 in the Ranitidine Syrup market.

  1. International Formulations, i.e. formulation exports (2015-16 sales: ?651.67 crores, or 58.13% of net sales) to 30-plus countries, with an enhanced focus on the US.
  2. APIs (2015-16 sales: ?100.56 crores)


Aside from this, JBCPL also provides contract manufacturing services for tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups and capsules – domestically and internationally to pharmaceutical companies in USA, UK, Australia, Brazil, Canada and South Africa.


Strategic Business Units (SBUs)

JBCPL’s 6 strategic business units (SBUs) comprise:

  1. India (22 major therapeutic groups, and 108 brands)
  2. Russia & CIS (prescription brands and contract manufacturing for OTC products)
  3. Global (generic products and branded formulations, accounting for over 30% of the company’s total turnover)
  4. Contrast Media {one of India’s top 3 companies for high osmolar contrast media (HOCM) and low osmolar contrast media (LOCM)}.
  5. APIs
  6. Business Development in areas such as contract manufacturing; joint ventures, distribution and marketing; in-licensing, and India sales network


Business Highlights

As of 31 March 2016, JB Chemicals & Pharmaceuticals Limited (JBCPL), reported:

  • Total revenues from operations amounting to ?1,148.16 crores, out of which exports accounted for ~58.13%
  • 17 internationally approved manufacturing units
  • 1 R&D Centre
  • A #35 rank in the domestic industry market (as per IMS MAT, March 2016)
  • 3 brands featuring among the top 300 brands (as per IMS MAT, March 2016)
  • Specialty products including pharmaceutical dosage forms like tablets, injectables, creams and ointments, lozenges, herbal liquids and capsules


JB Chemicals & Pharmaceuticals Limited (JBCPL) is listed on the National Stock Exchange of India (NSE) and the Bombay Stock Exchange (BSE).

For Johnson & Johnson


JB Chemicals & Pharmaceuticals Limited (JBCPL) at-a-glance


  • Employees 1,000+
  • Turnover (31 March, 2016) ~USD 173 million (or ~?1,148.16 crores)
    (i.e. total revenues from operations)
  • Manufacturing Facilities 17
  • R&D Centre 1
  • ANDAs Pending Approval with US FDA 5
  • International Patents Granted 24
  • Domestic Patents Granted 15

Approvals, etc.

  • US FDA
  • EU GMP
  • TGA Australia
  • MCC South Africa
  • MoH Japan
  • PIC/S (MoH, Ukraine)
  • Health Canada
  • NAFDAC Nigeria


JBCPL Annual Report – 2015-16




In December 1950, Mr. JB Mody started a partnership firm, M/s. Unique Pharmaceutical Laboratories. This was followed by the incorporation of JB Mody Chemicals & Pharmaceuticals Ltd. in December 1976.


Subsequently in June 1983, JBCPL acquired the pharmaceutical business of JB Mody & Bros., and in

March 1984, became a partner in M/s Unique Pharmaceutical Laboratories.


In March 1985, the assets of M/s Unique Pharmaceuticals Laboratories were dissolved and taken over by JB Mody Chemicals & Pharmaceuticals Ltd; in April 1985, Unique Chemicals (one of the partners in JB Chemicals & Pharmaceuticals Pvt. Ltd.) was amalgamated with JB Mody Chemicals & Pharmaceuticals Ltd; in June 1985, the shareholders of JB Chemicals & Pharmaceuticals Pvt. Ltd. were allotted 1,55,380 equity shares of ?100/- each, as fully paid up shares in the ratio of 1 share for every 17 held. JB Chemicals & Pharmaceuticals Pvt. Ltd. was then dissolved upon Mumbai High Court’s orders.


In August 1985, the company’s name was changed from JB Mody Chemicals & Pharmaceuticals Ltd. to JB Chemicals & Pharmaceuticals Ltd. (JBCPL).


For remaining details, see Milestones below.



  • 1976 – Incorporated as JB Mody Chemicals and Pharmaceuticals Ltd.
  • 1985 – Renamed JB Chemicals and Pharmaceuticals Ltd.
  • 1996-97 – Receives the prestigious National Export Award for 1996-97, from the Hon’ble Prime Minister of India
  • 1999 – Receives the IDMA Quality Excellence Award: Certificate of Merit for quality manufacturing at its manufacturing unit in Panoli, Gujarat
  • 2000 – Receives Golden Status certificate from the Government of India
  • 2001 – Receives:
    • First Award for Outstanding Export Performance of Pharmaceuticals in the large-scale manufacturer’s category from CHEMEXCIL
    • MCA approval (South Africa) for its tablets facility at Panoli, Gujarat
  • 2003
    • Files first ANDA with USFDA for Ciprofloxacin
    • Becomes the first company to market Rantac CD
    • Receives approval for Panoli facility from the Columbian Drug Regulatory Authority INVIMA
  • 2004
    • Features in Forbes “Best under $1 Billion” (Asia-Pacific)
    • Receives USFDA approval for marketing Ciprofloxacin tablets in the US
    • Receives USFDA approval for tablet manufacturing facility at Panoli, Gujarat
    • Receives UKMHRA approval for tablet manufacturing facility at Panoli, Gujarat
  • 2005
    • Receives TGA Australia approval for tablet manufacturing facility at Panoli, Gujarat
    • Receives USFDA approval to market Fluconazole tablets in the US
    • Features in Forbes Asia Pacific 200 List for “Best under a Billion” second year in a row
  • 2006
    • Receives the Niryat Shree Certificate of Excellence from Federation of Indian Export Organisations (FIEO) via Unique Pharmaceutical Laboratories Limited, a division of JBCPL, for outstanding export performance in Chemicals, Drugs, Pharma & Allied Products (Non-SSI) for 2004-05
    • Ranked second best for Excellence in Financial Reporting by the Institute of Chartered Accountants of India
  • 2007 – Receives merit certificate from South Asian Federation of Accountants (SAFA), an apex body of SAARC, for the Best Presented Accounts for 2005 in Hospitality, Health, Transport, Shipping, etc.
  • 2008 – Makes strategic investment in Biotech Laboratories, a South African company
  • 2011 – Divests its OTC portfolio in Russia, Ukraine and CIS to Johnson & Johnson





  • Chairman and Managing Director Mr. Jyotindra B. Mody
  • Whole Time Director (Administration) Mr. Dinesh B. Mody
  • Whole Time Director (Marketing) Mr. Shirish B. Mody
  • Independent Director Mr. Durga Dass Chopra
  • Whole Time Director (Planning & Development) Mr. Bharat P. Mehta
  • President & Whole time Director (Operations) Mr. Pranabh Mody
  • Independent Director Mr. Rajiv C. Mody
  • Executive Director (Technical & Production) Mr. Kamlesh L. Udani
  • Independent Director Dr. Satyanarain Agarwala
  • Independent Director Dr. Niranjan N. Maniar
  • Independent Director Mr. Jashvantrai B. Joshi
  • Independent Director Ms. Krupa R. Gandhi
  • Independent Director Mr. Devang R. Shah
  • Independent Director Mr. Shaukat H. Merchant





JB Chemicals & Pharmaceuticals Limited

Neelam Centre, ‘B’ Wing

4th floor, Hind Cycle Road

Worli, Mumbai 400 030

Maharashtra, India


Website: www.jbcpl.com

Tel: (022) 2482 2222/2493 0918

Fax: (022) 2493 0534

Email: secretarial@jbcpl.com







* Indicates mandatory field.
Please wait while comments are being sent...